Word search

Displaying 16 - 30 of 2500
Title Legend Grouping
ABPA and mucoid impaction Patient YML ABPA and mucoid impaction Image 1, Patient YML ABPA and mucoid impaction Image 2
Patient YML ABPA and mucoid impaction Image 1, Patient YML ABPA and mucoid impaction Image 2 ABPA and mucoid impaction
74 year old woman, known to have ABPA without asthma, bronchiectasis and oesophagitis and reflux. Presented originally age 68 years and improved with itraconazole. This was stopped and she continued on daily hypertonic saline nebulisers, with continuing cough. 
 
Relapsed with chronic cough and increasing breathlessness. She had a trachea deviated to the left and silent breath sounds in the left upper zone and left base. A bronchoscopy showed mucoid impaction and complete occlusion of the left upper and left lower lobes with thick mucus. This was removed with saline and suction, and distally the airways were normal. Her total and Aspergillus specific IgE had risen from 1100 kU/L and 13.0 kAU/L in August 2015 to 5100 kU/l and 21.6 kAU/L in November 2015. Her Aspergillus IgG also rose from 44mg/L to 102 mg/L over the same period.
 
She continued on prednisolone and itraconazole was restarted. She improved and her chest Xray abnormalities resolved.
 
Patient JSG: Nicotine stained fingers in ABPA with bronchiectasis Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day. Nicotine stained fingers - image 1, Nicotine stained fingers - image 2
Nicotine stained fingers - image 1, Nicotine stained fingers - image 2 Patient JSG: Nicotine stained fingers in ABPA with bronchiectasis Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
T-2307 The chemical structure of the novel arylamidine T-2307 T-2307
T-2307 T-2307 The chemical structure of the novel arylamidine T-2307
Laryngeal Aspergillosis, ptSA Laryngeal aspergillosis, probably related to inhaled corticosteroids. Image A., Image B., Image C., Image D.
Image A., Image B., Image C., Image D. Laryngeal Aspergillosis, ptSA Laryngeal aspergillosis, probably related to inhaled corticosteroids.
VL-2397 (ASP2397) VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two read more... VL-2397 (ASP2397)
VL-2397 (ASP2397) VL-2397 (ASP2397) VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two read more...
SCY-078 (MK-3118) SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118. SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor SCY-078 (MK-3118) SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
Biafungin acetate Biafungin acetate, a new echinocandin Biafungin acetate, a new echinocandin
Biafungin acetate, a new echinocandin Biafungin acetate Biafungin acetate, a new echinocandin
Primary Aspergillus pneumonia Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010 Pt DSM Community acquired primary Aspergillus pneumonia 05/03/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010
Pt DSM Community acquired primary Aspergillus pneumonia 05/03/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010 Primary Aspergillus pneumonia Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
Community acquired Aspergillus pneumonia July 2011 primary Aspergillus pneumonia (Pt LG)
MFIG launch Sept 2015: Dr Mike Bromley (Principle Investigator) Mike Bromley
MFIG launch Sept 2015: Dr Paul Bowyer (Principle Investigator) Paul Bowyer
MFIG launch Sept 2015: Dr Elaine Bignell (Deputy Director)
MFIG launch Sept 2014: Sir Robert Boyd, Prof Keith Gull, Prof Nick Read, Director MFIG Sir Robert Boyd,  Prof Keith Gull,  Prof Nick Read
MFIG launch Sept 2015: Sir Robert Boyd, Prof Keith Gull and Prof Nick Read Sir Robert Boyd, Prof Keith Gull and Prof Nick Read
Chronic pulmonary aspergillosis complicating Caplan’s syndrome Mr RM is 80 and an ex-coal miner.He developed pneumoconiosis from exposure to coal dust. He also developed rheumatoid arthritis and the combination of this disease and pneumoconiosis is called Caplan’s syndrome.His chest Xray in early 2015 shows read more... June 2014 image 1, June 2014 image 2, June 2014 image 3, June 2014 image 4, June 2014 image 5, June 2014 image 6, January 2014
June 2014 image 1, June 2014 image 2, June 2014 image 3, June 2014 image 4, June 2014 image 5, June 2014 image 6, January 2014 Chronic pulmonary aspergillosis complicating Caplan’s syndrome Mr RM is 80 and an ex-coal miner.He developed pneumoconiosis from exposure to coal dust. He also developed rheumatoid arthritis and the combination of this disease and pneumoconiosis is called Caplan’s syndrome.His chest Xray in early 2015 shows read more...

Pages